Search clinical trials for: MK-1064

Total 2089 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

Pharmacokinetics
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer
University of Sao Paulo

Completed

Laser Treatment Of Leg Telangiectasias

Leg Veins

Brazil
University of Miami

Completed

Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser (BCC)

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Mahidol University

Recruiting

The Safety and Efficacy of 1064-nm Picosecond Laser With Microlens Array for Pore Tightening; a Pilot Study

Enlarged Pores

Thailand
Aalborg University Hospital

Completed

Laser Treatment of Toenail Onychomycosis With a 1064 nm Nd:YAG-laser

Onychomycosis of Toenail

Denmark
Dominion Aesthetic Technologies, Inc.

Completed

Eon® Flanks Safety Clinical Study Protocol

Adipose Tissue

United States
Dominion Aesthetic Technologies, Inc.

Completed

Eon™ FR 1064 Full Abdomen Clinical Study Protocol

Abdominal Obesity

United States
Christopher Zachary

Recruiting

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Basal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Sciton

Completed

Laser Treatment of Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Dominion Aesthetic Technologies, Inc.

Completed

Eon™ FR Clinical Study Protocol 1064

Fat Disorder

United States
Stanford University

Completed

Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser

Onychomycosis

United States
Venus Concept

Recruiting

Electrical Muscle Stimulation With 1064 nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction.

Fat Reduction | Muscle Tone Increased

United States
Jason K Rivers, MD, FRCPC, FAAD
Cutera Inc.

Completed

Chart Review of the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis

Onychomycosis
Cairo University

Not yet recruiting

Carboxytherapy Versus Short-pulsed Nd Yag Laser in Cellulite

Efficacy of Treatment of Cellulite Using Carboxy Therapy
University of California, Irvine
Beckman Laser Institute University of California Irvine

Completed

Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser

Vascular Lesion

United States
University of California, Irvine
Candela Corporation

Completed

Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening (IH062905)

Localized Lipodystrophy

United States
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Cairo University

Completed

Long-pulsed 1064 nm Nd-YAG Laser Versus TCA 20% in Treatment of Keratosis Pilaris

Keratosis Pilaris

Egypt
Henry Ford Health System

Completed

Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
Curacle Co., Ltd.
KCRN Research, LLC

Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Diabetic Macular Edema

United States
Forest Laboratories
University of Florida

Terminated

A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain (EUR-1066)

Chronic Pancreatitis

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Cutera Inc.

Withdrawn

Clinical Evaluation of Tattoo Removal Using a Novel Dual-Wavelength, Dual-Pulse Duration Laser

Laser Tattoo Removal

Canada
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Euclises Pharmaceuticals, Inc.

Recruiting

ECP-1014 Treatment for Patients With Solid Tumor Cancers

Solid Tumor

China
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
xjpfW
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; First Hospital... and other collaborators

Completed

A Clinical Observation of 1064-nm Q-Switched Fractional Laser Combined With Oral Tranexamic Acid on Treating of Melasma.

Melasma

China
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Repare Therapeutics

Recruiting

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

Advanced Solid Tumor

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension

3

Subscribe